More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...
As the end of the tax year approaches, those who are employed or receiving a pension may find themselves on the receiving end of a potentially daunting HMRC letter. These letters, known as Simple ...
With the end of the tax year approaching, people who are employed or receiving a pension may find themselves on the receiving end of a seemingly intimidating HMRC letter. Known as Simple ...
Learn more. I am writing in response to Joe Lawlor’s Jan. 30 article in the Press Herald titled “Health advocates unveil effort to protect discount drug program.” As reported, those ...
Sanofi’s hopes of getting its ... type 1 diabetes in the US have been dashed by the FDA. The US regulator has issued a complete response letter (CRL) for Lexicon Pharma-partnered sotagliflozin ...
Sanofi will present 24 abstracts, including four oral presentations and a late-breaking poster, across approved and investigational medicines at the American Academy of Allergy, Asthma and Immunology ...
The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and China, citing serious violations of current good manufacturing practice (CGMP) ...
Sanofi bought back a $3.1 billion stake held by cosmetics giant L’Oréal. Journavx, a non-opioid pain medication made by Vertex Pharmaceuticals, received approval for adults from the FDA. United ...
A significant public health alert has emerged as Walmart faces a critical recall involving thousands of bags of broccoli, with the Food and Drug Administration warning of potentially lethal ...
Targeting it for obesity was validated by rimonabant (brand name Acomplia), a Sanofi drug approved in Europe in 2006. But hitting CB1 receptors in the brain led to psychiatric effects. Those ...
Plus, the drug still has plenty of room left to grow in places like the U.S., Sanofi executives said on an analyst call Thursday. All told, Beyfortus generated 1.7 billion euros (about $1.8 ...